Abstract
Deep learning methods have been shown to achieve excellent performance on diagnostic tasks, but it is still an open challenge how to optimally combine them with expert knowledge and existing clinical decision pathways. This question is particularly important for the early detection of cancer, where high volume workflows might potentially benefit substantially from automated analysis. Here, we present a deep learning framework to analyse samples of the Cytosponge®-TFF3 test, a minimally invasive alternative to endoscopy, for detecting Barrett’s Esophagus, the main precursor of esophageal cancer. We trained and independently validated the framework on data from two clinical trials, analysing a combined total of 4,662 pathology slides from 2,331 patients. Our approach exploits screening patterns of expert gastrointestinal pathologists and established decision pathways to define eight triage classes of varying priority for manual expert review. By substituting manual review with automated review in low-priority classes, we can reduce pathologist workload by up to 66% while matching the diagnostic performance of expert pathologists. These results lay the foundation for tailored, semi-automated decision support systems embedded in clinical workflows.
Competing Interest Statement
The Cytosponge device technology and the associated TFF3 biomarker have been licensed to Covidien GI solutions (now owned by Medtronic) by the Medical Research Council. MG, MCO, and FM are named inventors on a patent pertaining to technoloogy applied in this work. RCF and MO are named inventors on patents pertaining to the Cytosponge and associated technology. MG, MO, and RCF are shareholders of Cyted Ltd, a company working on early detection technology.
Clinical Trial
ISRCTN12730505, ISRCTN68382401
Funding Statement
This research has been supported by Cancer Research UK (FM: C14303/A17197), the Medical Research Council (RCF: RG84369) and Cambridge University Hospitals NHS Foundation Trust. BEST2 was funded by Cancer Research UK (12088 and 16893). MG acknowledges support from an Enrichment Fellowship from the Alan Turing Institute. MCO acknowledges support from a Borysiewicz Fellowship from the University of Cambridge and Junior Research Fellowship from Trinity College, Cambridge. FM is a Royal Society Wolfson Research Merit Award holder.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
BEST2: Ethics approval was obtained from the East of England - Cambridge Central Research Ethics Committee (number 10/H0308/71) and registered in the UK Clinical Research Network Study Portfolio (9461). BEST3: Ethics approval was obtained from the East of England - Cambridge Central Research Ethics Committee (number 16/EE/0546).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵a These authors share senior authorship.
Data Availability
The dataset is governed by data usage policies specified by the data controller (University of Cambridge, Cancer Research UK). We are committed to complying with Cancer Research UK's Data Sharing and Preservation Policy. Whole-slide images used in this study will be available for non-commercial research purposes upon approval by a Data Access Committee due to institutional requirements. Applications for data access should be directed to rcf29{at}cam.ac.uk. Data derived from the raw images are freely available at a public repository: https://github.com/markowetzlab/cytosponge-triage. The code and included data enable replication of the results and figures in this manuscript.
